NKGN Stock Alert: The Alzheimer’s News That Has NKGen Biotech Soaring Today


  • NKGen Biotech (NKGN) stock is up Monday on a clinical trial update.
  • The company can move forward with its Phase 2 Alzheimer’s treatment trial.
  • This follows positive data from its Phase 1 study.
NKGN Stock - NKGN Stock Alert: The Alzheimer’s News That Has NKGen Biotech Soaring Today

Source: pathdoc / Shutterstock.com

NKGen Biotech (NASDAQ:NKGN) stock is taking off on Monday after the clinical-stage biotechnology company got an update on its Phase 2 clinical trial.

The company says its Safety Review Committee has given it the go-ahead to start its Phase 2 clinical study of SNK01, a drug in development to treat moderate Alzheimer’s.

This comes after it reported stellar results from its Phase 1 clinical trial. That includes improved or maintained cognitive abilities after four doses. There were also no adverse effects from the treatment.

This new trial will have NKGen Biotech treating a larger number of patients for a longer period of time. That will result in 20 patients getting 20 doses of SNK01 while 10 get 10 placebo doses.

NKGen Biotech chairman and CEO Paul Song said the following about the news:

“We are also very encouraged with the clinical progress we have made to date in moderate Alzheimer’s disease research and look forward to generating additional significant clinical and biomarker data from our randomized placebo-controlled Phase 2 trial.”

NKGN Stock Movement Today

With this news comes heavy trading of NKGN stock on Monday. That has more than 26 million shares on the move as of this writing. This is well above its daily average trading volume of 3.7 million shares.

NKGN stock is up 54% as of Monday morning.

There are more stock market stories worth reading about below!

We have all of the hottest stock market news for traders to read up on for Monday! Among that is a bull stance for the S&P 500 and the latest on Tantech (NASDAQ:TANH) and Li Auto (NASDAQ:LI) shares. All of this news is ready at the links below!

More Monday Stock Market News

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. 

Read More: Penny Stocks — How to Profit Without Getting Scammed 

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Article printed from InvestorPlace Media, https://investorplace.com/2024/05/nkgn-stock-alert-the-alzheimers-news-that-has-nkgen-biotech-soaring-today/.

©2024 InvestorPlace Media, LLC